Arovella Therapeutics Ltd has released a press release.
Positive FDA Type D Meeting Outcome
Filed with ASX ·
6ix hasn’t read this filing yet.
Arovella Therapeutics Limited on 6ix
In the deck
Earlier from Arovella Therapeutics
- CLDN18.2 CAR-T cells eliminate pancreatic cancer cells
- Arovella receives R&D tax rebate of $3.21 million
- S&P DJI Announces September 2025 Quarterly Rebalance
- Appendix 4E and Annual Report
- S&P DJI Announces March 2025 Quarterly Rebalance
Later from Arovella Therapeutics
- Arovella Therapeutics appoints former CSL CSO Dr Andrew Nash as Non-executive Director
- Quarterly Activities/Appendix 4C Cash Flow Report
- ALA's ind for ALA-101 accepted by the U.S.FDA
- Half Year Report and Appendix 4D
- CLDN18.2 CAR iNKT Cell Preclinical Data Update
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics